Updated · University of Minnesota Twin Cities · Jun 3
CEPI Grants POP Biotechnologies $9.7 Million for H5N1 Vaccine Platform
Updated
Updated · University of Minnesota Twin Cities · Jun 3
CEPI Grants POP Biotechnologies $9.7 Million for H5N1 Vaccine Platform
3 articles · Updated · University of Minnesota Twin Cities · Jun 3
Summary
$9.7 million in new CEPI funding will push POP Biotechnologies’ nanoparticle vaccine platform toward a phase 1 trial for an H5N1 avian flu candidate.
The money supports further development of the company’s SNAP protein platform, designed to speed creation of nanoparticle-based vaccines against epidemic and pandemic threats.
POP says the same platform, if successful, could be adapted rapidly for a future “Disease X,” extending its use beyond the immediate H5N1 program.
Can new 'plug-and-play' vaccine technology truly outpace the threat of a future 'Disease X' pandemic?
With top NIH scientists caught smuggling mpox, what other dangerous pathogens might be slipping through U.S. border controls?
CEPI Invests $9.7 Million to Accelerate SNAP™ Nanoparticle H5N1 Vaccine: A New Era for Rapid, Equitable Pandemic Preparedness
Overview
On June 3, 2026, CEPI announced a major new investment of up to $9.7 million to support POP Biotechnologies in advancing their SNAP™ nanoparticle vaccine platform into Phase 1 clinical trials for H5N1 avian influenza. This builds on an earlier partnership that began in July 2025, when CEPI provided an initial $1.5 million, laying the foundation for current progress. The continued financial support highlights the urgency of developing effective vaccines against potential H5N1 outbreaks and demonstrates CEPI’s commitment to accelerating innovative solutions for global health security.